ASX:IVX

Invion (IVX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
471,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IVX stock logo

About Invion Stock (ASX:IVX)

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

IVX Stock News Headlines

InVision Software AG IVX
FW: 234x Gain
This coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.
Stocks in August are DROPPING – Here’s Why
Gas Prices About to Skyrocket, Gas Economics 101
FW: 234x Gain
This coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.
Doctor Who 1960s movies get price cut
Meta Sparks a Sharp Sell-off in Tech Stocks
Markets Today: Global Stocks Slide as Bond Yields Climb
Man charged in Indiana County home invasion
See More Headlines
Receive IVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invion and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,500,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.39 million

Miscellaneous

Outstanding Shares
6,420,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
1.15
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Thian Chew
    Executive Chairman & CEO
  • Ms. Melanie Jaye Leydin B.Bus (Age 51)
    C.A., Chief Financial Officer
  • Dr. Dean Naylor
    Head of Intellectual Property Development
  • Ms. Claire Newstead-Sinclair C.A.
    Company Secretary

IVX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Invion own?
This page (ASX:IVX) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners